Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innovation and Patient Access

In October of 2018, the Trump Administration outlined a proposal that would import foreign price controls for medicines covered under Medicare Part B. Despite warnings from BIO and dozens of other industry experts and patient advocates, the administration continues to defend its flawed plan and with equally flawed rhetoric.
In a recent blog for Vital Transformation, author Duane Schulthess examines a claim made by Secretary Azar at a Brookings Institute briefing where he touts the plan – k